Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

IMAC HOLDINGS, INC.

(BACK)
  Report
Delayed Nasdaq  -  04:00 2022-09-30 pm EDT
0.3790 USD   +0.58%
09/26Imac Holdings, Inc. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)
AQ
09/09IMAC Holdings, Inc. Announces Completion of Third Cohort of its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson's Disease
GL
09/09IMAC Holdings, Inc. Announces Completion of Third Cohort of its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson's Disease
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

IMAC : Announces $3.9 Million Registered Direct and Private Placement - Form 8-K

08/15/2022 | 05:59pm EDT

IMAC Holdings, Inc. Announces $3.9 Million Registered Direct and Private Placement

BRENTWOOD, Tenn., August 12, 2022 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) ("IMAC" or the "Company"), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments, today announced that it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 5,164,474 shares of common stock at a purchase price of $0.76 per share in a registered direct offering.

In a concurrent private placement, the Company also agreed to issue to the investors Series 1 warrants to purchase 5,164,474 shares of common stock that will become exercisable on the date that is six months following the date of issuance of the shares of common stock in the registered direct offering (the "Exercise Date") and expire on the five year anniversary of the Exercise Date, at an exercise price of $0.95 per share, and Series 2 warrants to purchase 5,164,474 shares of common stock that will become exercisable on the Exercise Date and expire on the one year anniversary of the Exercise Date, at an exercise price of $0.95 per share. The aggregate gross proceeds to the Company of both transactions are expected to be approximately $3.9 million before deducting the placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for working capital and other general corporate purposes, including financing the costs of implementing the Company's strategic alternatives activities.

The transactions are expected to close on or about August 16, 2022, subject to the satisfaction of customary closing conditions.

Joseph Gunnar & Co., LLC is acting as the Sole Placement Agent.

The registered direct offering is being made pursuant to an effective shelf registration statement on Form S-3 (No. 333-237455) previously filed with the U.S. Securities and Exchange Commission (the "SEC") and declared effective by the SEC on April 3, 2020. A final prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, by contacting Joseph Gunnar & Co., LLC Attention: Syndicate Department at 30 Broad Street, 11th floor, New York, NY 10004 or by telephone at (212) 440-9600.

The offer and sale of the securities in the private placement are being made in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The securities were offered only to accredited investors. Pursuant to a securities purchase agreement with the investors, the Company has agreed to file a registration statements with the SEC covering the resale of the common stock issuable upon exercise of the warrants.

Before investing in this offering, interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About IMAC Holdings, Inc.

IMAC Holdings owns and manages health and wellness centers that deliver sports medicine, orthopedic care, and restorative joint and tissue therapies for movement restricting pain and neurodegenerative diseases. IMAC is comprised of three business segments: outpatient medical centers, The Back Space, and a clinical research division. With treatments to address both young and aging populations, IMAC Holdings owns or manages outpatient medical clinics that deliver regenerative rehabilitation services as a minimally invasive approach to acute and chronic musculoskeletal and neurological health problems. IMAC's The Back Company retail spinal health and wellness treatment centers deliver chiropractic care within Walmart locations. IMAC's research division is currently conducting a Phase I clinical trial evaluating a mesenchymal stem cell therapy candidate for bradykinesia due to Parkinson's disease. For more information visit www.imacholdings.com.

Safe Harbor Statement

This press release contains forward-looking statements. These forward-looking statements, and terms such as "anticipate," "expect," "believe," "may," "will," "should" or other comparable terms, are based largely on IMAC's expectations and are subject to a number of risks and uncertainties, certain of which are beyond IMAC's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, risks and uncertainties associated with its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the skills and experience necessary to meet customers' requirements, and its ability to protect its intellectual property. IMAC encourages you to review other factors that may affect its future results in its registration statement and in its other filings with the Securities and Exchange Commission. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this press release will in fact occur.

IMAC Press Contact:

Laura Fristoe

lfristoe@imacrc.com

Disclaimer

IMAC Holdings Inc. published this content on 15 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 August 2022 21:57:31 UTC.


© Publicnow 2022
All news about IMAC HOLDINGS, INC.
09/26Imac Holdings, Inc. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule o..
AQ
09/09IMAC Holdings, Inc. Announces Completion of Third Cohort of its Phase 1 Clinical Study ..
GL
09/09IMAC Holdings, Inc. Announces Completion of Third Cohort of its Phase 1 Clinical Study ..
AQ
09/09IMAC Holdings, Inc. Announces Completion of Third Cohort of Its Phase 1 Clinical Study ..
CI
09/07Biote Enters Partnership to Add Certain Services to IMAC Holdings' Network of Clinics
MT
09/07Biote Announces Strategic Partnership with IMAC Holdings, Inc.
GL
09/01IMAC Holdings, Inc. Announces Addition of Medical Weight Loss Services to IMAC Regenera..
GL
09/01IMAC Holdings, Inc. Announces Addition of Medical Weight Loss Services to IMAC Regenera..
AQ
09/01IMAC Holdings, Inc. Announces Addition of Medical Weight Loss Services to IMAC Regenera..
CI
08/16IMAC Holdings, Inc. Announces Closing of $3.9 Million Registered Direct and Private Pla..
GL
More news
Analyst Recommendations on IMAC HOLDINGS, INC.
More recommendations
Financials (USD)
Sales 2022 19,0 M - -
Net income 2022 -10,0 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,08x
Yield 2022 -
Capitalization 12,3 M 12,3 M -
Capi. / Sales 2022 0,65x
Capi. / Sales 2023 0,51x
Nbr of Employees 166
Free-Float 77,2%
Chart IMAC HOLDINGS, INC.
Duration : Period :
IMAC Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IMAC HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 0,38 $
Average target price 5,00 $
Spread / Average Target 1 219%
EPS Revisions
Managers and Directors
Jeffrey S. Ervin Chairman & Chief Executive Officer
Matthew C. Wallis President & Executive Director
Sheri Gardzina Controller & Executive Vice President-Finance
Ben Lerner Chief Operating Officer
Evans E. Maurice Independent Director
Sector and Competitors
1st jan.Capi. (M$)
IMAC HOLDINGS, INC.-66.75%12
AIER EYE HOSPITAL GROUP CO., LTD.-11.90%28 383
BANGKOK DUSIT MEDICAL SERVICES28.26%12 421
FRESENIUS SE & CO. KGAA-37.99%12 123
IHH HEALTHCARE-19.62%11 179
RAMSAY HEALTH CARE LIMITED-19.89%8 406